VANCOUVER, British Columbia, Dec. 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced it has secured a US$3.0 million term loan from Silicon Valley Bank ("SVB"). The Company plans to use funds from any draw down of the loan to support continued development of its product pipeline and for general corporate purposes.
